Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Genetic Testing
Germline Variants Linked to High Heritability and Worse Outcomes in Pediatric Neuroblastoma
By
Phoebe Starr
Genetic Testing
June 2021, Vol 12, No 3
Researchers have identified 2 inherited pathogenic genetic variants in patients with pediatric neuroblastoma, according to results from a study presented at the 2021 virtual American Association for Cancer Research annual meeting. Both variants—the
ALK
gene and loss of function in
PHOX2B
—are associated with worse outcomes.
Read Article
New Genetic Test May Give Early Warning of Aggressive Prostate Cancers
By
Charles Bankhead
Genetic Testing
,
Personalized Medicine
October 2016, Vol 7, No 9
Read Article
Cervical Cancer Screening Only Marginally Improved
By
Rosemary Frei, MSc
Genetic Testing
,
In the Literature
,
Personalized Medicine
June 2010, Vol 1, No 2
A new study suggests that removing financial incentives for screening for cervical cancer, diabetic retinopathy, and hypertension and diabetes control reduces performance, including screening rates. The study was published online in May in the
British Medical Journal
(2010;340:c1898).
Read Article
Genetic Testing as Simple as 1-2-3
Genetic Testing
,
IMPAKT Breast Cancer Conference
,
Personalized Medicine
June 2010, Vol 1, No 2
Brussels—A simple genetic test using only 3 genes is among the most effective means of classifying breast cancer into the subtypes that indicate pa tients’ different prognoses and response or resistance to cancer therapies, say researchers, and this finding could allow greater use of personalized treatments in breast cancer.
Read Article
Breast and Ovarian Cancer Testing After the Myriad Genetics Decision
By
Rosemary Frei, MSc
Genetic Testing
,
Personalized Medicine
June 2010, Vol 1, No 2
There’s no question that when, on March 29, a federal district court judge ruled the patents held by Myriad Genetics to the
BRCA1
and
2
gene mutation sequences are invalid, a shock went through the healthcare and genetics communities.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma